Retour
Fourchette du Jour
15,95 €
16,57 €
Fourchette 52 Semaines
9,24 €
19,00 €
Volume
645 549
Moyenne 50J / 200J
15,86 €
/
14,09 €
Clôture Précédente
16,60 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (627 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -4,5 | 0,3 |
| P/B | 8,7 | 2,9 |
| ROE % | -121,5 | 3,7 |
| Net Margin % | — | 3,8 |
| Rev Growth 5Y % | — | 10,0 |
| D/E | 0,1 | 0,2 |
Objectif de Cours des Analystes
Hold
32,33 €
+96.4%
Low: 28,00 €
High: 37,00 €
BPA Prévisionnel
-2,57 €
CA Est.
62 M
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2030 |
3,08 €
2,72 € – 3,32 €
|
510 M | 2 |
| FY2029 |
1,96 €
1,73 € – 2,11 €
|
420 M | 2 |
| FY2028 |
0,45 €
-2,80 € – 7,86 €
|
300 M | 6 |
Insider Trading Activity
Buy ratio (90d)
0.0%
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 9, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
sell | 6 693 | 16,08 € | 107 633 € |
| Mar 6, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
other | 31 250 | — | — |
| Feb 23, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
sell | 10 034 | 15,57 € | 156 197 € |
| Feb 21, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
other | 46 500 | — | — |
| Feb 18, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
sell | 1 038 | 15,00 € | 15 570 € |
| Feb 18, 2026 |
Yea Christopher
CHIEF DEVELOPMENT OFFICER
|
sell | 1 109 | 15,00 € | 16 635 € |
| Feb 18, 2026 |
Audhya Paul K.
CHIEF MEDICAL OFFICER
|
sell | 1 163 | 15,00 € | 17 445 € |
| Feb 17, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
other | 4 838 | — | — |
| Feb 17, 2026 |
Yea Christopher
CHIEF DEVELOPMENT OFFICER
|
other | 3 548 | — | — |
| Feb 17, 2026 |
Audhya Paul K.
CHIEF MEDICAL OFFICER
|
other | 4 838 | — | — |
| Feb 12, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
sell | 3 354 | 15,70 € | 52 658 € |
| Feb 11, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
other | 14 240 | — | — |
| Jan 16, 2026 |
Audhya Paul K.
CHIEF MEDICAL OFFICER
|
grant | 100 000 | — | — |
| Jan 16, 2026 |
Sweeny Nicole
Chief Commercial Officer
|
grant | 100 000 | — | — |
| Jan 16, 2026 |
Arif Bilal
Chief Operations Officer
|
grant | 49 000 | — | — |
| Dec 8, 2025 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
sell | 7 294 | 16,51 € | 120 424 € |
| Dec 6, 2025 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
other | 31 250 | — | — |
| Nov 24, 2025 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
sell | 10 940 | 13,45 € | 147 154 € |
| Nov 24, 2025 |
Yea Christopher
CHIEF DEVELOPMENT OFFICER
|
sell | 4 331 | 13,45 € | 58 256 € |
| Nov 24, 2025 |
Piekos Brian
Chief Financial Officer
|
sell | 4 471 | 13,45 € | 60 139 € |
Points Clés
Debt/Equity of 0,07 — conservative balance sheet
Negative free cash flow of -153,34M
Croissance
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-121,50%
ROIC-138,64%
Net MarginN/A
Op. MarginN/A
Sécurité
Debt / Equity
0,07
Current Ratio5,35
Interest Coverage-32,50
Valorisation
P/E Ratio
-4,54
P/B Ratio8,72
EV/EBITDAN/A
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -183,44M |
| ROE | -121,50% | ROA | -73,15% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -153,34M |
| ROIC | -138,64% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,07 | Current Ratio | 5,35 |
| Interest Coverage | -32,50 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | -4,54 | P/B Ratio | 8,72 |
| P/S Ratio | N/A | PEG Ratio | -0,51 |
| EV/EBITDA | N/A | Dividend Yield | 0,00% |
| Market Cap | 831,99M | Enterprise Value | 739,65M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Net Income | -183,44M | -126,64M | -92,91M | -82,34M | -46,24M |
| EPS (Diluted) | -3,69 | -3,44 | -3,33 | -3,36 | -2,33 |
| Gross Profit | 0,0 | -86,17M | 0,0 | 0,0 | -41,29M |
| Operating Income | -188,00M | -140,45M | -110,87M | -96,61M | -57,92M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 250,77M | 235,40M | 183,20M | 203,88M | 272,01M |
| Total Liabilities | 155,38M | 28,82M | 22,18M | 18,79M | 14,82M |
| Shareholders' Equity | 95,39M | 206,58M | 161,03M | 185,09M | 257,19M |
| Total Debt | 6,31M | 7,32M | 8,23M | 8,19M | 5,91M |
| Cash & Equivalents | 98,64M | 31,79M | 56,24M | 30,73M | 50,59M |
| Current Assets | 241,69M | 225,69M | 172,33M | 193,65M | 264,26M |
| Current Liabilities | 45,17M | 22,81M | 15,03M | 11,58M | 9,77M |